TY - JOUR
T1 - The impact of the COVID-19 pandemic lockdown measures on the prescribing trends and utilization of opioids in the English primary care setting
T2 - segmented-liner regression analysis
AU - Nawaf Sindi, Oula
AU - Alshaikh, Faisal Salman
AU - Godman, Brian
AU - Kurdi, Amanj
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022/6/27
Y1 - 2022/6/27
N2 - Background: The COVID-19 lockdown has resulted in limited access to most of the conventional chronic pain management services. Subsequently, changes in opioids’ utilization could be expected. This study assessed the impact of the first COVID-19 lockdown on opioid utilization using aggregated-level, community dispensing dataset covering the whole English population. Research design and methods: A segmented-linear regression analysis was applied to monthly dispensed opioid prescriptions from March 2019 to March 2021. Opioid utilization was measured using the number of opioids’ items dispensed/1000 inhabitants and Defined Daily Dose (DDD)/1000 inhabitants/day during 12-months pre/post the lockdown in March 2020 stratified by strong and weak opioids. Results: For all opioids’ classes, there were nonsignificant changes in the number of opioids’ items dispensed/1000 inhabitants trend pre-lockdown, small increases in their level immediately post-lockdown, and a non-significant decline in the trend post-lockdown. Similarly, a non-significant reduction in the DDD/1000 inhabitant/day baseline trend pre-lockdown, nonsignificant immediate increases in the level post-lockdown, and declines in the trend post-lockdown for all opioids’ classes were observed. Conclusion: Unexpectedly, opioid utilization does not appear to have been significantly affected by the lockdown measures during the study period. However, patient-level data is needed to determine more accurate estimates of any changes in the opioid prescribing including incident prescribing/use.
AB - Background: The COVID-19 lockdown has resulted in limited access to most of the conventional chronic pain management services. Subsequently, changes in opioids’ utilization could be expected. This study assessed the impact of the first COVID-19 lockdown on opioid utilization using aggregated-level, community dispensing dataset covering the whole English population. Research design and methods: A segmented-linear regression analysis was applied to monthly dispensed opioid prescriptions from March 2019 to March 2021. Opioid utilization was measured using the number of opioids’ items dispensed/1000 inhabitants and Defined Daily Dose (DDD)/1000 inhabitants/day during 12-months pre/post the lockdown in March 2020 stratified by strong and weak opioids. Results: For all opioids’ classes, there were nonsignificant changes in the number of opioids’ items dispensed/1000 inhabitants trend pre-lockdown, small increases in their level immediately post-lockdown, and a non-significant decline in the trend post-lockdown. Similarly, a non-significant reduction in the DDD/1000 inhabitant/day baseline trend pre-lockdown, nonsignificant immediate increases in the level post-lockdown, and declines in the trend post-lockdown for all opioids’ classes were observed. Conclusion: Unexpectedly, opioid utilization does not appear to have been significantly affected by the lockdown measures during the study period. However, patient-level data is needed to determine more accurate estimates of any changes in the opioid prescribing including incident prescribing/use.
KW - COVID-19
KW - England
KW - Opioids
KW - lockdown
KW - utilization trends
UR - http://www.scopus.com/inward/record.url?scp=85132999153&partnerID=8YFLogxK
U2 - 10.1080/17512433.2022.2093715
DO - 10.1080/17512433.2022.2093715
M3 - Article
C2 - 35733237
AN - SCOPUS:85132999153
SN - 1751-2433
JO - Expert Review of Clinical Pharmacology
JF - Expert Review of Clinical Pharmacology
ER -